High Blood Pressure Medicines Show Promise for Treating Heart Disease

Oct 29, 2009
C. Michael White, professor of pharmacy practice. Photo by Peter Morenus

(PhysOrg.com) -- Two medications commonly used to treat high blood pressure appear to be effective in treating one of the most common and potentially deadly forms of heart disease, according to a report by UConn scientists.

Treatment featuring the two medications - angiotensin-converting enzyme inhibitors, or ACE inhibitors, and angiotensin receptor blockers, or ARBs - can lead to a reduction in risk of death, risk of , and risk of stroke, and fewer hospitalizations for heart failure for patients suffering from stable ischemic heart disease, the researchers say in an article published this month in Annals of Internal Medicine.

However, the drugs have risks of their own. Risks associated with ACE inhibitors include a persistent cough, sudden fainting, too much in the blood, and dangerously low blood pressure (hypotension). Risks associated with ARBs include too much potassium in the blood and low blood pressure.
Center director C. Michael White, a professor of pharmacy practice at UConn, says people with stable ischemic heart disease may not need to take both medications to achieve the most beneficial results.

“People with advanced coronary artery disease benefit from adding or ARB therapy to the standard drugs they are already taking,” White says. “However, we found there are no additional benefits and an increased risk of side effects to taking both drugs together.”

White was joined in the research by Craig Coleman, an associate professor of pharmacy practice at UConn and the Center’s co-director, and William Baker, a senior research scientist and an assistant professor of pharmacy practice at the University. The study, a comparative effectiveness review of recent research, was funded by the U.S. Department of Health and Human Services’ Agency for Healthcare Research and Quality (AHRQ).

“Stable ischemic heart disease is a major cause of death in the United States, so these findings are very encouraging,” says AHRQ Director Carolyn M. Clancy. “This comparative effectiveness report will be a useful tool for patients to help them work with their clinicians to make choices on treatment.”

Stable ischemic heart disease occurs when the flow of oxygen-rich blood to the heart is reduced because of narrowed or blocked arteries. Symptoms of stable ischemic heart disease include decreased tolerance of exercise, and severe chest pain on exertion (known as angina), which afflicts about 9 million U.S. adults. Long-term risks of stable ischemic heart disease include heart failure and heart attack. Overall, heart disease is among the nation’s most common and deadly illnesses, afflicting nearly 80 million Americans and killing nearly 2,400 every day.

Standard treatment for stable ischemic heart disease consists of a modification of diet, exercise, and medications including aspirin, anti-cholesterol drugs, nitroglycerin, and beta blockers. These can keep the disease from worsening. However, while standard treatment usually alleviates chest pains, it is not universally successful in reducing risk of heart failure or heart attack.

For patients with advanced stable ischemic heart disease, treatment can include heart surgery or angioplasty (a procedure in which a catheter is used to inflate a balloon inside the plaque-narrowed artery).

ACE inhibitors and ARBs, commonly prescribed to combat , also are used for treatment of a heart attack and chronic heart failure. ARBs, first approved for use in the United States in the mid-1990s, often are prescribed when a patient has adverse effects to ACE inhibitors, but ACE inhibitors are used more commonly.

UConn researchers found that patients with stable ischemic who take an ACE inhibitor in addition to standard treatment can reduce the likelihood of several negative outcomes, including death from heart attack or heart failure, non-fatal heart attacks, hospitalization for heart failure, and revascularization (surgeries that reroute blood to the heart). Patients who take an ARB in addition to standard medications can reduce their risk of death from a heart-related cause, heart attack or stroke.

“Both types of drugs reduce blood pressure, help maintain potassium levels in the blood, and help the heart remodel better after being damaged by a heart attack,” says Baker. “ACE inhibitors prevent angiotensin II from being made, while ARBs block angiotensin II from having their deleterious effects on the body.”

While some patients and clinicians pursue a course of treatment using both ACE inhibitors and ARBs, the researchers found that combined treatment does not show any benefit over an ACE inhibitor alone, and that risks include fainting, diarrhea, low blood pressure, and kidney problems.

“In some diseases, like and diabetic kidney disease, using an ACE inhibitor and ARB together is better than either drug alone,” says White, a University Teaching Fellow and Fellow of the American College of Clinical Pharmacists and American College of Clinical Pharmacologists. “However, that is not the case here. We found no additional benefits from using two of them versus only one of them, while there is an increased risk of side effects.”
The researchers found that existing studies provide little data on the medications’ benefits or harms in specific populations such as people of different genders, ethnicity, diabetic status, or those who have or don’t have high .

More information: The report can be found at: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotension II-Receptor Blockers for Ischemic Heart Disease.

Provided by University of Connecticut (news : web)

Explore further: FDA OKs Merck tablet to reduce ragweed allergies

add to favorites email to friend print save as pdf

Related Stories

Aspirin in Heart Attack Prevention: How Much, How Long?

Jan 15, 2008

A low dose of aspirin appears to be just as effective as a higher dose in preventing a heart attack, stroke or death among patients with stable cardiovascular disease, say researchers at Duke University Medical Center.

Enzyme is key to clogged arteries

Sep 24, 2009

Scientists at Queen Mary, University of London have made an important discovery in understanding what causes arteries to clog up.

Recommended for you

Study recalculates costs of combination vaccines

11 hours ago

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

15 hours ago

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

Pyridoxine-doxylamine drug safety data lacking

Apr 16, 2014

(Medical Xpress)—The most commonly prescribed drug for pregnant women suffering from morning sickness in their first trimester does not prevent birth defects even though drug safety data says it does, according to research ...

User comments : 0

More news stories

Leeches help save woman's ear after pit bull mauling

(HealthDay)—A pit bull attack in July 2013 left a 19-year-old woman with her left ear ripped from her head, leaving an open wound. After preserving the ear, the surgical team started with a reconnection ...

Scientists tether lionfish to Cayman reefs

Research done by U.S. scientists in the Cayman Islands suggests that native predators can be trained to gobble up invasive lionfish that colonize regional reefs and voraciously prey on juvenile marine creatures.

Venture investments jump to $9.5B in 1Q

Funding for U.S. startup companies soared 57 percent in the first quarter to a level not seen since 2001, as venture capitalists piled more money into an increasing number of deals, according to a report due out Friday.

White House updating online privacy policy

A new Obama administration privacy policy out Friday explains how the government will gather the user data of online visitors to WhiteHouse.gov, mobile apps and social media sites. It also clarifies that ...